StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Next report date, year-over-year trend, and recent quarter history.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $0.15 | $0.15 | -0.32% | 0.1M |
| 05-19 | $0.14 | $0.15 | +5.24% | 0.1M |
| 05-20 | $0.14 | $0.15 | +7.77% | 0.1M |
| 05-21 | $0.14 | $0.15 | +6.43% | 0.1M |
| 05-22 | $0.15 | $0.15 | -0.74% | 0.2M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
BLUE BIOFUELS INC
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Each factor shows BIOF's percentile within the scored universe — observational ranking, not a recommendation.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2019 2019-12-31 |
|---|---|
Revenue | $60.00K |
Operating Income | $-1.78M |
Net Income | $1.01M |
EPS (Diluted) | $0.01 |
Total Assets | $609.59K |
Total Liabilities | $3.94M |
Cash & Equivalents | $110.63K |
Free Cash Flow OCF − CapEx | Not available |
Shares Outstanding | 219.51M |
No sell-side coverage available for BIOF yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.